Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This study is looking into a new treatment, ABBV-142, for adults with Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare lung disease that causes scarring and breathing difficulties. The study aims to see how safe ABBV-142 is, how well people tolerate it (meaning how well they can handle any side effects), and if it helps improve lung function. You might be able to join if you've been diagnosed with IPF within the last seven years, and your diagnosis is confirmed by a recent chest scan. The study will compare ABBV-142 to a placebo (an inactive substance). Researchers will measure changes in your lung capacity (Forced Vital Capacity or FVC) after 24 weeks and track any side effects for up to about 52 weeks. The study plans to enroll 165 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study with an estimated enrollment of 165 participants. It is a platform study, meaning it can evaluate different treatments over time.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be monitored for adverse events for up to approximately 52 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
At a glance
Conditions
NCT07230288
Where you'd take part
This study runs at 57 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Acibadem City Clinic Tokuda University Hospital EAD /ID# 277846
Sofia, Bulgariano site contact published
Recruiting
Caritas-Krankenhaus St. Maria gGmbH /ID# 278138
Donaustauf, Bavaria, Germanyno site contact published
Recruiting
Centre d'Investigation Clinique Mauricie /ID# 277949
Trois-Rivières, Quebec, Canadano site contact published
Recruiting
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou /ID# 278333
Rennes, Ille-et-Vilaine, Franceno site contact published
Recruiting
China Medical University Hospital /ID# 278039
Taichung, Taiwanno site contact published
Recruiting
Christie Clinic on University /ID# 277871
Champaign, Illinoisno site contact published
Recruiting
Clinical Research Specialists - Kissimmee /ID# 279184
Kissimmee, Floridano site contact published
Recruiting
Diagnostic Consultative Center Convex /ID# 277848
Sofia, Bulgariano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- ABBVIE INC. · STUDY_DIRECTOR · AbbVie
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Exclusion
What this trial measures
- Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL)Week 24
FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.
- Percentage of Participants with Adverse Events (AE)Up to approximately 52 weeks
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.